论文部分内容阅读
目的:评价抗幽门螺杆菌感染药物与“三联疗法”对胃溃疡患者的临床疗效及其对炎症因子水平的影响。方法:选取2015年8月—2016年8月间收治的胃溃疡患者80例临床资料,采用随机数表法将患者分为雷贝拉唑三联组(n=40)和埃索美拉唑镁三联组(n=40);雷贝拉唑三联组患者给予雷贝拉唑、克拉霉素和阿莫西林三联疗法治疗,埃索美拉唑镁三联组患者给予埃索美拉唑镁、克拉霉素和阿莫西林三联疗法治疗,评价两组患者治疗后的总有效率、复发率、不良反应的发生率以及对白介素-2(IL-2)和IL-6测得值的变化情况。结果:雷贝拉唑三联组患者治疗后的总有效率、6月后复发率、不良反应的发生率与埃索美拉唑镁三联组相比其差异无统计学意义(P>0.05);埃索美拉唑镁三联组患者治疗后血清IL-2水平高于雷贝拉唑三联组,而IL-6水平低于雷贝拉唑三联组(P<0.05)。结论:采用埃索美拉唑镁三联疗法抗幽门螺杆菌感染的胃溃疡患者,其疗效优于雷贝拉唑三联疗法。
Objective: To evaluate the clinical efficacy of anti-Helicobacter pylori infection and triple therapy in patients with gastric ulcer and its effect on the level of inflammatory cytokines. Methods: The clinical data of 80 patients with gastric ulcer admitted from August 2015 to August 2016 were selected. The patients were divided into rabeprazole triple group (n = 40) and esomeprazole magnesium Triple therapy group (n = 40); rabeprazole triple therapy group given rabeprazole, clarithromycin and amoxicillin triple therapy, esomeprazole magnesium triple group patients given esomeprazole magnesium, carat And amoxicillin triple therapy, evaluation of the total effective rate, recurrence rate, the incidence of adverse reactions and the changes of IL-2 and IL-6 measured after treatment . Results: The total effective rate, the relapse rate after 6 months, the incidence of adverse reactions in rabeprazole triple therapy group were not significantly different from those in esomeprazole magnesium triple therapy group (P> 0.05). The level of serum IL-2 in esophagone triad group was higher than that in rabeprazole triple therapy group, while the level of IL-6 was lower than that in rabeprazole triple therapy group (P <0.05). CONCLUSIONS: Gastric ulcer patients treated with esomeprazole magnesium triple therapy against Helicobacter pylori are superior to rabeprazole triple therapy in patients with gastric ulcer.